Mid April, we were quoted a potential time frame of within...

Mid April, we were quoted a potential time frame of within 3months for FDA feedback on the trial design and dose selection.

Further, my guess is they have enough dough in the bank to see out CY 2024 given we weren’t hit by a mac truck last quarterly report (if you recall I was nervous about this without the fda submission occuring on time).

My guess is also, on the back of a positive response from the FDA, Paul, Beverley, SW and Matt will have the content to formalise funding arrangements. Why? Because our dose of 2mg has been studied in 2x phase 2b trials, we have proven ourselves to conduct a phase 3 trial (stage1)and the team will have the data to point to for the metrics of the phase 3 (n of subjects, how it is monitored) and the cost will be known, as will the outcome (within a a level of probability to obtain funds; deal, debt, cap raise or combination of those).

Then the market can get back to being excited again, like we all were from 005.

These are my ramblings. Would be happy to step aside and hear the opposite thesis but that is not worth pondering is it?

DYOR